Brighton Jones LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brighton Jones LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.89M	Buy	+5,699	New	+$1.94M	0.04%	280
2025 Q4	–	Sell	-4,941	Closed	-$2.25M	–	91
2025 Q3	$2.25M	Buy	4,941 +3,909	+379%	+$1.59M	0.05%	203
2025 Q2	$336K	Sell	1,032 -177	-15%	-$49K	0.01%	673
2025 Q1	$326K	Buy	1,209 +177	+17%	+$45.5K	0.01%	509
2024 Q4	$243K	Buy	+1,032	New	+$271K	0.01%	590
2023 Q4	–	Sell	-3,912	Closed	-$693K	–	584
2023 Q3	$693K	Buy	3,912 +136	+4%	+$25.9K	0.04%	230
2023 Q2	$717K	Buy	3,776 +23	+0.6%	+$4.56K	0.04%	239
2023 Q1	$752K	Buy	+3,753	New	+$789K	0.04%	218
2018 Q3	–	Sell	-3,957	Closed	-$390K	–	284
2018 Q2	$390K	Sell	3,957 -47	-1%	-$4.66K	0.05%	200
2018 Q1	$477K	Sell	4,004 -18	-0.4%	-$2.32K	0.07%	162
2017 Q4	$511K	Buy	4,022 +11	+0.3%	+$1.38K	0.06%	149
2017 Q3	$471K	Hold	4,011	–	–	0.06%	159
2017 Q2	$320K	Buy	+4,011	New	+$256K	0.05%	189
2016 Q4	–	Sell	-3,919	Closed	-$266K	–	107
2016 Q3	$266K	Buy	+3,919	New	+$276K	0.04%	194

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brighton Jones LLC's ALNY Position: Q1 2026 in Review

Brighton Jones LLC opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2026: 5,699 shares worth $1.89M. The stake represents 0.04% of the portfolio and ranks #280 among its holdings. This is a return to the name: Brighton Jones LLC previously reported a position in ALNY as recently as Q3 2025.

Brighton Jones LLC first reported a position in ALNY in Q3 2016 and has held it in 14 quarters since. The position peaked at $2.25M in Q3 2025. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Brighton Jones LLC held 5,699 shares of Alnylam Pharmaceuticals worth $1.89M as of Q1 2026.
Alnylam Pharmaceuticals was a new Brighton Jones LLC position in Q1 2026.
Alnylam Pharmaceuticals made up 0.04% of Brighton Jones LLC's portfolio in Q1 2026, its #280 holding.
Brighton Jones LLC first reported a position in Alnylam Pharmaceuticals in Q3 2016 and has held it in 14 quarters since.
Brighton Jones LLC's Alnylam Pharmaceuticals position peaked at $2.25M in Q3 2025.
789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Brighton Jones LLC's 13F filing for Q1 2026, filed 28 Apr 2026.